# Stage 1 — Bucket 5 Completion Log

**Date:** 2026-05-23
**Status:** COMPLETED (files written by subagent successfully)
**Agent tool uses:** 36 | Tokens: 48,100

## Confirmed key citations

| Paper | Confirmed PMID | Note |
|---|---|---|
| Mormont et al. 2000 (Clin Cancer Res — rest-activity rhythm + OS) | **10955782** | ⚠️ task brief listed 10955784; PMID corrected |
| Roenneberg et al. 2003 (J Biol Rhythms — MCTQ original) | 12568247 | CONFIRMED ✓ |
| Horne & Östberg 1976 (Int J Chronobiol — MEQ original) | 1027738 | CONFIRMED ✓ |
| Lewy & Sack 1989 (Chronobiol Int — DLMO methodology) | **2706705** | ⚠️ task brief listed 2656100; PMID corrected |
| Mormont & Lévi 2003 (Cancer — cancer chronotherapy review) | **12491517** | ⚠️ task brief listed 12491492; PMID corrected |
| Innominato 2009 Annals of Medicine | ❌ DOES NOT EXIST | PMID 19034842 = unrelated medical education editorial; correct paper = Innominato 2014 Annals of Med PMID 24915535 |
| Innominato 2012 fatigue/weight loss Cancer | ❌ PMID WRONG | PMID 22213170 = unrelated hepatocarcinogenesis paper; fatigue/weight loss paper needs manual PubMed search |

**5 of 7 key papers confirmed; 2 have PMID errors requiring library resolution.**

## NEW high-priority papers identified (not in prompt.md)

| Paper | PMID | Importance |
|---|---|---|
| Cash et al. 2018 (Psycho-Oncology) — HNSCC-specific actigraphy predicts 2-year OS (n=55) | 30117225 | **CRITICAL — only HNSCC-specific actigraphy-survival study** |
| Abusamak et al. 2025 (Int J Cancer) — HNSCC chronotherapy meta-analysis; morning RT reduces grade ≥3 mucositis by 31% | 39508699 | **CRITICAL — highest-quality evidence specifically in HNSCC** |
| Ortiz-Tudela / Innominato 2016 (BMC Cancer) — TAP multi-parameter wearable sensor | 27102330 | High — feasibility tool for future trial design |
| Lévi, Innominato 2020 (Cancers) — tele-monitoring in GI cancer | 32708950 | Moderate — wearable monitoring validation |
| Innominato 2014 (Annals of Medicine) — circadian timing system in clinical oncology | 24915535 | High — correct citation for the "Annals of Med 2009" reference |
| Innominato et al. 2012 (Int J Cancer) — actigraphy predicts survival in CRC | 22488038 | High — confirms Mormont 2000 in a prospective cohort |

## Most feasible monitoring tools for HNSCC CRT trial

1. **MEQ at enrollment** (zero burden, zero cost, chronotype screen in 5 min)
2. **Wrist actigraphy 7 days pre-CRT + repeat week 3** (I<O dichotomy index, IS, IV) — validated by Mormont 2000 + Innominato 2012; HNSCC feasibility by Cash 2018
3. **TAP composite sensor** (temperature + activity + position) for circadian-phenotyping substudy

## HNSCC-specific findings

- **Cash et al. 2018**: 55 HNSCC patients, pre-CRT actigraphy predicts 2-year OS (nighttime restfulness HR=0.91, p=0.009)
- **Abusamak et al. 2025**: Morning RT reduces grade ≥3 mucositis by 31% in HNSCC meta-analysis
- Inter-individual circadian variation up to 12 hours — confirms individual phase (not clock time) must drive scheduling

## Key trial design recommendation (for Section 7)

MEQ at registration + 7-day pre-CRT actigraphy (I<O, IS, IV) to stratify by circadian robustness → dexamethasone timing documented relative to individual phase → repeat actigraphy week 3 detects treatment-induced disruption.

## Files confirmed
- info/bucket5_monitoring_trial_design.md (26,498 bytes)
- reference/bucket5_inaccessible.md (8,050 bytes)
